Background: TRAIL/Apo2L is a pro-apoptotic ligand of the TNF family that engages the apoptotic machinery through two pro-apoptotic receptors, TRAIL-R1 and TRAIL-R2. This cell death program is tightly controlled by two antagonistic receptors, TRAIL-R3 and TRAIL-R4, both devoid of a functional death domain, an intracellular region of the receptor, required for the recruitment and the activation of initiator caspases. Upon TRAIL-binding, TRAIL-R4 forms a heteromeric complex with the agonistic receptor TRAIL-R2 leading to reduced caspase-8 activation and apoptosis.
Introduction
TRAIL/Apo2L is regarded as a promising anticancer agent for cancer therapy and is currently being evaluated in clinical trials [1] . TRAIL binds to four membrane-anchored receptors: TRAIL-R1 (DR4), TRAIL-R2 (DR5, Killer, TRICK), TRAIL-R3 (DcR1, LIT, TRID) or TRAIL-R4 (DcR2, TRUNDD), and one soluble receptor, osteoprotegerin (OPG) [1] . TRAIL induces cell death through its interaction with either TRAIL-R1 or TRAIL-R2. These two agonistic receptors harbor, within their cytoplasmic region, a relatively small amino acid stretch called the death domain (DD), which is necessary and sufficient to transduce the death signal [2] . Activation of TRAIL-R1 or TRAIL-R2 by trimeric TRAIL induces the recruitment of the adaptor protein FADD (Fas-associated death domain protein) via homotypic interactions with their respective DD, allowing in turn the recruitment of the initiator caspases, procaspases-8 and -10 [3, 4] , leading to the formation of the death-inducing signaling complex (DISC) [5] . Within the DISC, the initiator caspases-8 and -10 undergo catalytic cleavage inducing their release to the cytosol and the triggering of the caspase cascade that ultimately leads to apoptosis. In contrast, TRAIL binding to TRAIL-R3 or TRAIL-R4 fails to induce the apoptotic machinery because none of these receptors harbor a functional DD [6] . TRAIL-R3 is anchored to the membrane via its glycosyl-phosphatidylinositol tail (GPI), whereas TRAIL-R4 is addressed to the cell surface through a transmembrane domain but includes a truncated DD that is unable to recruit the adaptor protein FADD [7] .
Expression of TRAIL-R3 or TRAIL-R4 confers resistance to TRAIL-induced cell death in several tumor cell lines and primary tumors [8, 9, 10, 11, 12, 13] . These antagonistic receptors, coined ''decoy receptors'', were initially proposed to act as competitors to TRAIL-R1 and TRAIL-R2 for TRAIL binding [14] . However, we and others have provided evidence that TRAIL-R4 should rather be considered as a regulatory receptor, because TRAIL-R4 is able to interact with TRAIL-R2 within the TRAIL DISC and to impair caspase-8 activation [10, 12, 15] . In this study, we provide new evidence that TRAIL-R4 exhibits a TRAIL-independent signaling activity that gives rise to oncogenic-like properties in HeLa cells, mainly through the activation of Akt.
Results

TRAIL-R4 ectopic expression in HeLa cells markedly changes cell morphology, cell proliferation and tumor growth
Ectopic TRAIL-R4 expression to physiological levels in HeLa cells ( Figure 1A) , as well as in other tumors [15] , by use of retroviral vectors, affords good selective protection against TRAIL-induced cell death, but not Fas ligand ( Figure 1B and C). Strikingly, HeLa cells expressing TRAIL-R4 (H-TRAIL-R4) undergo drastic morphological changes including cell rounding and loss of adherence ( Figure 1D ). As compared to control cells (H-Ctl) infected with an empty vector, H-TRAIL-R4 cells exhibited a higher proliferative index ( Figure 1E ). This increase in cell proliferation is however most likely independent of TRAIL itself, since the recombinant fusion protein Fc-TRAIL-R2 failed to affect proliferation in H-TRAIL-R4 cells ( Figure S1A ). In agreement with these findings, TRAIL levels were undetectable in the supernatant or at the surface of H-TRAIL-R4 cells (not shown). The drastic changes in cell morphology and proliferative status prompted us to check whether TRAIL-R4 overexpression confers tumor growth advantage in vivo. Parental (H-Ctl) and TRAIL-R4 expressing cells (H-TRAIL-R4) were implanted into nude mice in the left and the right flank, respectively of the same animal (Fig. S1B ) and tumor growth was followed for 32 days ( Figure 1F ). Remarkably, TRAIL-R4 expressing HeLa cells exhibited a clear tumor growth advantage as compared to control cells in nude mice.
We next checked whether TRAIL-R4 ectopic expression affected cell proliferation in two other TRAIL-sensitive tumor cell lines, the Jurkat T cell lymphoma and the colon carcinoma SW480. To address this question, Jurkat and SW480 cell lines were infected with an empty vector (J-Ctl and SW-Ctl) or a retroviral vector encoding TRAIL-R4 (J-TRAIL-R4 and SW-TRAIL-R4). Expression levels of TRAIL-R4 and TRAIL-R2 were analyzed by flow cytometry (Figure 2A and B) and cell sensitivity to TRAIL-induced cell death was determined by PMS-MTS assay. Similar to HeLa cells, ectopic expression of TRAIL-R4 in Jurkat or SW480 cells inhibited TRAIL-induced cell death in a dose-dependent manner ( Figure 2C and D). TRAIL-R4 expression, however, induced no particular modification of cell proliferation as compared to control cells ( Figure 2E and F), and no change in cell morphology could be observed (not shown).
TRAIL-R4-mediated constitutive Akt activation in HeLa cells contributes to cell resistance to TRAIL-induced apoptosis and to increased cell proliferation
To explore the molecular basis of the deregulated death commitment and proliferation potential in HeLa cells expressing TRAIL-R4 ectopically, we next analyzed the activation status of Akt, a survival pathway that plays a central role in diverse cellular functions, including survival, growth, and proliferation [16] .
Strikingly, while Akt appeared to be constitutively activated in Jurkat and SW480 cells irrespective of TRAIL-R4 ectopic expression, a differential Akt phosphorylation profile was detected in H-TRAIL-R4 cells as compared to control parental HeLa cells ( Figure 3A ). Constitutive activation of Akt in HeLa cells was TRAILindependent as TRAIL stimulation only marginally induced Akt phosphorylation in H-Ctl cells ( Figure 3B ). Activation of Akt in these cells appeared to be restricted to TRAIL-R4. Accordingly, ectopic expression of TRAIL-R3 ( Figure 3B ), TRAIL-R2 (not shown) or a chimeric TRAIL receptor encoding the extracellular domain of TRAIL-R1 fused to TRAIL-R2 ( Figure S2 ) induced no change in Akt activation, contrary to a chimeric construct encoding TRAIL-R4 intracellular domain ( Figure S2 ). Inhibition of Akt phosphorylation either using siRNA targeting the regulatory subunit of PI3K ( Figure 3C ), or by over-expressing PTEN ( Figure 3D ) sensitized H-TRAIL-R4 cells to TRAIL-induced cell death, indicating that cell resistance to TRAIL in these cells is, at least partly, due to the sustained activation of the Akt pathway. Accordingly, the pharmacological inhibitor of Akt phosphorylation, LY294002, significantly restored TRAIL-induced apoptosis in H-TRAIL-R4 cells ( Figure 4A) . Notably, sensitization to TRAIL-induced cell death was not associated with an increase in caspase-8 cleavage, but rather with an increase in caspase-3 processing ( Figure 4B and C), suggesting that Akt-mediated inhibition most likely occurs downstream of the TRAIL DISC probably at the mitochondrial or post mitochondrial level. Remarkably, LY294002 reduced H-TRAIL-R4-mediated cell proliferation to levels comparable to those of control parental cells ( Figure 4D ).
Altogether our findings suggest that TRAIL-R4 in HeLa cells is a regulatory receptor whose anti-apoptotic functions involve both TRAIL DISC targeting and activation of the Akt survival pathway. Discussion TRAIL is an attractive anti-tumoral agent owing to its ability to selectively induce apoptosis in tumor cells [17, 18] and thus TRAIL derivatives or recombinant TRAIL preparations have entered clinical trials [1] . The molecular mechanisms governing TRAIL-induced cell death or signal transduction remain, however, only partially understood. Cell resistance to TRAIL-induced cell death can arise (100 mM) then stimulated or not with TRAIL (500 ng/ml) for 24 hours and apoptosis was analyzed after Hoechst staining. These results are representative of at least 3 independent experiments. Mean percentage of apoptotic cells and SD are shown (mean 6 SD). ***P,0.001, one-way ANOVA with Bonferroni's multiple comparison test. (B) Cells were stimulated either with LY294002 (100 mM) then treated or not with TRAIL as above and cell lysates were processed by western blot for the analysis of Akt phosphorylation, caspase-8 and active caspase-3. Filled arrows show caspase cleavage products. The empty arrow shows full length caspase-8. Densitometry analysis of caspase-3 p17 and caspase-8 full-length immunoreactive bands were obtained using ImageJ software, normalized with respect to GAPDH, and plotted in (C). (D) Cellular growth in the presence or the absence of Akt inhibitor LY294002 (10 mM) was monitored during 4 days by flow cytometry analysis using CFSE. LY294002 was applied every day to the cell culture supernatant to afford sustained inhibition of Akt. doi:10.1371/journal.pone.0019679.g004
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PLoS ONE | www.plosone.orgboth from the inhibition of the apoptotic machinery, or more specifically from the deregulation of the expression and/or the functionality of TRAIL receptors. Likewise, loss of TRAIL-R1 or TRAIL-R2 expression [19, 20, 21, 22] or expression of TRAIL-R3 or TRAIL-R4, two main antagonistic receptors [9, 10, 11, 12, 13] , abrogate TRAIL-induced cell death selectively, without affecting the apoptotic machinery triggered by other members of the TNF family, nor the intrinsic pathway. Likewise, overexpression of TRAIL-R4 protects tumor cells against TRAIL-induced cell death by regulating caspase-8 activation at the DISC level [10, 15] .
In the present study, we provide evidence that TRAIL-R4 in HeLa cells a) partially protects from TRAIL-induced apoptosis and b) enhances cell proliferation index through Akt activation in a TRAIL-independent manner. Remarkably, TRAIL-R4-mediated Akt activation in HeLa cells leads to drastic morphological changes, such as reduced cell size and loss of adhesion, suggesting that TRAIL-R4 may exhibit pro-metastatic properties ( Figure 5 ). These findings, however, may be restricted to tumor cell lines expressing low levels of active Akt, since contrary to HeLa cells, no morphological or proliferative changes were detected in Jurkat and SW480 cells, which express high levels of active Akt. Our findings nonetheless clearly suggest, for the first time, that TRAIL-R4 exhibits unexpected signaling properties conferring cellular growth advantage both in vitro and in vivo.
Besides apoptosis triggering, and depending on the cell line or type, TRAIL stimulation can induce non apoptotic signaling pathways including Akt [23, 24, 25, 26] , NF-kB [27] or MAPK [28, 29] , cell proliferation [26, 30, 31] or differentiation [32, 33, 34] . It has recently been proposed that the activation of non apoptotic signaling pathways by TRAIL involve the formation of a cytosolic secondary complex which, contrary to TNF [35] , allows the recruitment of adaptor proteins and kinases including TRAF2, RIP or NEMO [36] . Activation of Akt by TRAIL-R4 in HeLa cells by such a secondary complex is unlikely, as this pathway appears to be activated in a TRAIL-ligand independent manner. Moreover, we have not yet been able to identify this secondary complex (not shown).
How TRAIL-R4 mediates Akt activation in HeLa cells remains unknown for the moment. TRAIL-R4 shares relatively high homology with TRAIL-R1 and TRAIL-R2 [7] and is the only TRAIL antagonistic receptor that harbors an intracellular domain. Interestingly, ectopic expression of the TRAIL-R4 intracellular domain in HeLa cells induces constitutive AKT activation. This domain would therefore provide an ideal docking site for a putative binding partner. It is therefore tempting to speculate that the intracellular domain of TRAIL-R4 may interact with membrane associated or cytosolic proteins already known to bind to TRAIL-R1 or TRAIL-R2 such as GSK3 [37] , ARAP1 [38] , DAP3 [39] , Burton's tyrosine kinase [40] , or PRTM5 [41] . The exact molecular mechanism involved in this regulation therefore needs to be further investigated.
Altogether, our findings indicate for the first time that, besides inhibiting TRAIL-induced cell death, TRAIL-R4 is able to regulate the PI3K/Akt signaling pathway in cell type-dependent manner leading to cell resistance to apoptosis and to enhanced cellular growth.
Materials and Methods
Reagents and antibodies
His-tagged recombinant soluble human TRAIL and Fc-TRAIL-R2 were produced and used as described previously [42] . For Western blotting experiments, anti-GAPDH, anti-PI3K, anti-HSC70 were obtained from Santa Cruz Biotechnology (CA, USA), anti-phosphoAkt from Upstate (Milipore, Molsheim, France), anti-Akt, and anti-PTEN from Cell Signaling (Ozyme, Saint Quentin Yvelines, France). Antibodies used for flow cytometry, anti-TRAIL-R1 (wB-K32), anti-TRAIL-R2 (B-L27), anti-TRAIL-R3 (wB-B44), anti-TRAIL-R4 (wB-P30), and anti-TRAIL were from Diaclone (Besançon, France). The PI3K/AKt inhibitor LY294002 was purchased from Cell Signaling (Ozyme, Saint Quentin Yvelines, France).
Cell culture and transfection
HeLa (human cervix carcinoma), SW480 (Colon carcinoma) and Jurkat cells (T Lymphoma) were obtained from the ATCC. HeLa and SW480 cells were cultured in high-glucose Dulbecco's modified Eagle's medium (Sigma-Aldrich, Lyon, France) supplemented with 10% fetal calf serum (Gibco-BRL, Erigny, France), and Jurkat cells were cultured in RMPI as above. Transfection of HeLa cells was carried out using JetsiENDO TM reagent (Eurogentec, Angers, France), according to the manufacturer's instructions using the following PI3K siRNA (59-GGGUGUGGAUUACACCAUU-39) and siRNA control (Invitrogen, Cergy Pontoise, France). PTEN transfections were performed with the pSG5L-HA-PTEN construct (kindly provided by Dr William Sellers, Dana-Farber Cancer Institute, Boston) using TransPEI TM (Eurogentec).
Retroviral production and cell transduction
The retroviral vector pMSCVpuro and the generation of viruses have previously been described (30) . TRAIL-R4 full-length construct was subcloned from a pCR-3 vector (Invitrogen) to the retroviral vector pMSCV-puro as a HindII-XhoI fragment. HeLa cells were transduced for 16 hours with viral supernatants containing polybrene (8 mg/ml), washed in phosphate buffered saline (PBS), and selected in complete medium containing puromycin (2.5 mg/ml).
Measurement of cell viability and apoptosis
Cell viability assays were performed in 96-well plates. 10 4 cells per well were incubated at 37uC for 24 hours with increasing concentrations of His-TRAIL (from 0 to 10,000 ng/ml). Cell viability was determined by the PMS/MTS method, according to the manufacturer's specifications (Promega, Madison, WI, USA.). Apoptosis was assessed by Hoechst staining by determining the percentage of condensed nuclei from at least 300 cells per condition. For Akt inhibition, cells were pretreated with LY294002 (100 mM) one hour before TRAIL treatment (500 ng/ml, 5 hours). PI3K inhibition and PTEN expression were measured 48 and 24 hours hours after transfection respectively and cells were simultaneously treated 5 hours with 500 ng/ml of His-TRAIL.
Cell proliferation
To measure cell proliferation the different cellular populations were plated at the same density and counted each day. CellTrace TM CFSE Cell Proliferation Kit (Molecular Probes, Invitrogen) was used to measure cell proliferation using a LSRII flow cytometer (DB Biosciences) and the ModFIT Software (Verity Software House Topsham, ME) was applied to determine the proliferation index.
Western blotting
Lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Nonspecific binding sites were blocked in PBS containing 0.05% Tween 20 and 5% powdered milk. Immunoblots were then incubated with specific primary antibody, followed by horseradish peroxidase-conjugated secondary antibody, and developed by the enhanced chemiluminescence method according to the manufacturer's protocol (Pierce, Rockford, IL).
In vivo studies
Six weeks old female athymic nude mice (Harlan, Le Malcourle, Gannat) were subcutaneously xenografted with 1610 6 H-Ctl in the right flank and 1610 6 H-TRAIL-R4 in the left flank (n = 10). Tumor volume was obtained after caliper measurement of the tumor and the formula (l6l6L)/2 with l the smaller and L the higher dimension. Figure S1 (A) The proliferative index of H-Ctl and H-TRAIL-R4 cells was measured in the presence or in the absence of 10 mg recombinant Fc-TRAIL-R2, as described in the manuscript Figure 1E . Fc-TRAIL-R2 was added to the culture daily for 4 days. (B) Representative picture of nude mice xenografted with HeLa control (H-Ctl on the left flank) and HeLa expressing TRAIL-R4 (H-TRAIL-R4 on the right flank) and the corresponding tumors harvested from mice pictured. (TIFF) Figure S2 (A) Schematic representation of TRAIL receptor chimeric constructs (OM043, OM050 and OM051). Vectors were constructed using standard cloning procedures. TRAIL-R2 and TRAIL-R4 intracellular domains (icd) were obtained by polymerase chain reaction from pCRIII vectors encoding full length TRAIL-R2 and TRAIL-R4 as described earlier [10] , with the following primer pairs: TRAIL-R2 forward primer (59-GTC GAC TGT TCT CTC TCA GGC ATC-39); reverse primer (59-CTC GAG CGG CCG CCA GTG TGA TGG-39) and TRAIL-R4 forward primer (59-GTC GAC TAT CAC TAC CTT ATC ATC -39); reverse primer (59-CTC GAG TCA CAG GCA GGA CGT AGC -39) containing a SalI and a XhoI site. Oligonucleotide primers and Pfu polymerase were purchased from Eurogentech (Angers, France) and Sigma-Aldrich (Lyon, France) respectively. The resulting amplified fragments were subcloned into pCR-Blunt (Invitrogen, Cergy Pontoise, France) and checked by sequencing. TRAIL-R2-icd and TRAIL-R4-icd were subcloned between the SalI and XhoI sites of pCRIII vectors encoding the extracellular domains (ecd) of TRAIL-R1 (aa 1-239, PS688), TRAIL-R2 (aa 1-212, PS664) or TRAIL-R4 (aa1-211, PS690), kindly provided by Dr Pascal Schneider (Lausanne, Switzerland). Resulting TRAIL-R1ecd-TRAIL-R2icd, TRAILR4ecd-TRAIL-R2icd and TRAIL-R2ecd-TRAIL-R4icd DNA fragments were subcloned into a pMSCV-Puro retroviral vector between HindIII and XhoI, generating pMSCV-Puro-TRAILR1ecd-TRAIL-R2icd (OM043), pMSCV-Puro-TRAIL-R4ecd-TRAIL-R2icd (OM051) and pMSCV-Puro-TRAIL-R2ecd-TRAIL-R4icd (OM050). (B) Receptor expression in HeLa cells was analyzed by flow cytometry after infection of TRAIL receptor fusion constructs (OM043, OM050 and OM051) or the corresponding empty vector (OM181). (C) Biochemical analysis of TRAIL chimeric receptors. Immunoprecipitations were performed using a control antibody (lanes 1, 4, 7, 10, 13 and 16) or antibodies targeting TRAIL-R1 (lanes 2, 3, 5 and 6), TRAIL-R2 (lanes 8, 9, 11 and 12) and TRAIL-R4 (lanes 14, 15, 17 and 18) from DIACLONE (Besançon, France). Antibodies were applied either after lysis (1, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16 and 18) , or on intact cells (2, 5, 8, 11, 14 and 17) for 1 h on ice. The latter samples were subsequently subjected to lysis in NP40 lysis buffer and samples were precleared on sepharose 6B beads before immunoprecipitation using agarose protein G beads. Samples were then washed extensively and subjected to western blot using anti-TRAIL-R1, -R2 and -R4 antibodies from Milipore (Molsheim, France). Note that TRAIL-R4's extracellular domain is not recognized by the anti-TRAIL-R4 antibody from Chemicon. *ns stands for non specific. (D) AKT activation was analyzed by western blot as described in the text. (TIFF)
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